CGLGX | RPFCX | CGLGX / RPFCX | |
Total Expense Ratio | 0.37 | 0.98 | 38% |
Annual Report Gross Expense Ratio | 0.42 | 0.98 | 43% |
Fund Existence | 5 years | 33 years | - |
Gain YTD | 12.469 | 11.211 | 111% |
Front Load | N/A | 5% | - |
Min. Initial Investment | 250 | 1000 | 25% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 20.5B | 274M | 7,482% |
Annual Yield % from dividends | 1.87 | 1.51 | 124% |
Returns for 1 year | 12.66 | 9.75 | 130% |
Returns for 3 years | 34.99 | 37.36 | 94% |
Returns for 5 years | N/A | 74.04 | - |
Returns for 10 years | N/A | 106.23 | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
HLHIX | 27.29 | 0.35 | +1.30% |
Virtus KAR Health Sciences Inst | |||
APHMX | 46.09 | 0.13 | +0.28% |
Artisan Mid Cap Institutional | |||
PRWCX | 37.95 | -0.01 | -0.03% |
T. Rowe Price Capital Appreciation | |||
GCMRX | 35.53 | -0.21 | -0.59% |
Goldman Sachs Mid Cap Value R | |||
ETNMX | 14.74 | -0.09 | -0.61% |
Eventide Balanced Fund Class N |